Skip to main content
. 2020 Jun 28;21(13):4595. doi: 10.3390/ijms21134595

Figure 3.

Figure 3

Dose-response curves of NSCLC-cell lines treated with the DNMTIs decitabine and zebularine; shading discriminates male (blue) and female (pink) cell lines. EGFR/KRAS mutation is indicated by an X between the two curves of a cell line.